Advertisement

Effect of Primary Hypertension on Treatment Outcomes of Patients with Postmenopausal Osteoporosis: A 5 Year Follow Up Retrospective Study

  • Volkan YilmazEmail author
  • Ebru Umay
  • Ibrahim Gundogdu
  • Fatma Aytul Cakcı
Original Article

Abstract

Aim

To investigate the efficacy of primary hypertension (HTN) on the treatment prognosis of patients with postmenopausal osteoporosis (PMOP).

Methods

45 patients who were diagnosed as PMOP with lumbar and/or femur neck bone mineral density screening (BMD) but have no history of PMOP treatment including calcium and vitamin D, have comorbid primary HTN and treated with a vasodilator antihypertensive drug at least a year were included to the study. Control group was constituted with 44 patients with PMOP at same age but have no comorbidity. Demographic features including age, height, weight, occupation, educational level menarche and menopause age, clothing style, daily intake of calcium, smoking and/or alcohol consumption, daily physical activity level, personal history of fragility fracture or in mother and duration of primary HTN diagnosis were recorded. Biochemical parameters were also recorded. Patients were treated with bisphosphonate, calcium and vitamin D and same parameters were evaluated at the end of first and fifth year.

Results

Demographic and disease characteristics were not different between groups before treatment (p > 0.05). In group analysis, there was significant improvement in lumbar and femur neck T scores of PMOP + HT and PMOP groups after 1 and 5 years of treatment compared to baseline (p < 0.05) Lumbar and femur neck T score variations between the baseline, first and fifth years of treatment were not significantly different in PMOP + HT and PMOP groups (p < 0.05).

Conclusions

Although the results vary between populations, primary HTN does not have an impact on the prognosis of PMOP treatment in Turkish population.

Keywords

Primary hypertension Postmenopausal osteoporosis Treatment 

Notes

Compliance with Ethical Standards

Conflict of interest

Dr Yilmaz, Dr Umay, Dr Gundogdu and Dr Cakcı declare no disclosure or conflict of interest.

Ethical standards

All procedures performed in this study was in accordance with the ethical standards of Turkish Ministry of Health and Diskapi Yildirim Beyazit Training and Research Hospital research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006;119:S3–11.CrossRefGoogle Scholar
  2. 2.
    Lidfeldt J, Holmdahl L, Samsioe G, Nerbrand C, Nyberg P, Scherstén B, Agardh DC. The influence of hormonal status and features of the metabolic syndrome on bone density: a population-based study of Swedish women aged 50 to 59 years. The Women’s Health in the Lund Area Study. Metabolism. 2002;51:267–70.CrossRefGoogle Scholar
  3. 3.
    McGrowder D, Williams A, Gordon L. Hypocalciuria in pre-eclampsia and gestational hypertension due to decreased fractional excretion of calcium. Arch Med Sci. 2009;5:80–5.Google Scholar
  4. 4.
    Asaba Yutaro, Ito Masako, Fumoto Toshio, Watanabe Ken, Fukuhara R, Takeshita S, Nimura Y, Ishida J, Fukamizu A, Ikeda K. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009;24:241–50.CrossRefGoogle Scholar
  5. 5.
    Pérez-Castrillón JL, Justo I, Silva J, et al. Bone mass and bone modelling markers in hypertensive postmenopausal women. J Hum Hypertens. 2003;17:107–10.CrossRefGoogle Scholar
  6. 6.
    Gotoh M, Mizuno K, Ono Y, Takahashi M. High blood pressure, bone-mineral loss and insulin resistance in women. Hypertens Res. 2005;28:565–70.CrossRefGoogle Scholar
  7. 7.
    Belizan JM, Villar J, Gonzales L, Campodonico L, Bergel E. Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med. 1991;325:1399–405.CrossRefGoogle Scholar
  8. 8.
    Yazici S, Yazici M, Korkmaz U, Engin ME, Erdem BA, Erden I, Ozhan H, Ataoglu S. Relationship between blood pressure levels and bone mineral density in postmenopausal Turkish women. Arch Med Sci. 2011;7(2):264–70.CrossRefGoogle Scholar
  9. 9.
    Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly women: a prospective study. Lancet. 1999;354:971–5.CrossRefGoogle Scholar
  10. 10.
    Mussolino ME, Madans JH, Gillum RF. Bone mineral density and hypertension prevalance in postmenopausal women: result from Third National Health and Nutrition Examination Survey. Ann Epidemiol. 2006;16:395–9.CrossRefGoogle Scholar
  11. 11.
    Tsurusaki K, Ito M, Hayashi K. Differential effects of menopaus and metabolic disease on trabecular and cortical bone assessed by peripheral quantitative computed tomography (pQCT). Br J Radiol. 2000;73:14–22.CrossRefGoogle Scholar
  12. 12.
    Yilmaz V, Umay E, Gundogdu I, Tezel N. Effect of type 2 diabetes mellitus on treatment outcomes of patients with postmenopausal osteoporosis. J Diabetes Metab Disord. 2018.  https://doi.org/10.1007/s40200-018-0359-1.
  13. 13.
    Afghani A, Johnson CA. Resting blood pressure and bone mineral content are inversly related in overweight and obese Hispanic women. Am J Hypertens. 2006;19:286–92.CrossRefGoogle Scholar
  14. 14.
    Jankowska EA, Susanne C, Roguckay E, Medras M. The inverse relationship between bone status and blood pressure among Polish men. Ann Hum Biol. 2002;29:63–73.CrossRefGoogle Scholar
  15. 15.
    Larijani B, Bekheirnia MR, Soltani A, Khalili-Far A, Adibi H, Jalili RB. The bone mineral density is related to blood pressure in men. Am J Hum Biol. 2004;16:168–71.CrossRefGoogle Scholar
  16. 16.
    Yilmaz V, Umay E, Gundogdu I, Tezel N. Treatment outcomes of postmenopausal osteoporosisin patients with stable hypothyroidism: a 5 years follow up retrospective study. Erciyes Med J. 2018.  https://doi.org/10.5152/etd.2018.17065.
  17. 17.
    Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens. 2001;14:704–7.CrossRefGoogle Scholar
  18. 18.
    Strazzullo P. The renal calcium leak in primary hypertension: pathophysiological aspects and clinical implications. Nutr Metab Cardiovasc Dis. 1991;1:98–103.Google Scholar
  19. 19.
    Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol. 2000;13:169–77.PubMedGoogle Scholar
  20. 20.
    Cirillo M, Galletti F, Strazzullo P, Torielli L, Melloni MC. On the pathogenetic mechanism of hypercalciuria in genetically hypertensive rats of the Milan strain. Am J Hypertens. 1989;2:741–6.CrossRefGoogle Scholar
  21. 21.
    Lynn H, Kwok T, Wong SY, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone. 2006;38:584–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Physical Rehabilitation Medicine ClinicYildirim Beyazit Training and Research HospitalAnkaraTurkey

Personalised recommendations